17 November 2017 - - Palo Alto, California-based cancer treatment developer DNAmito, Inc. will integrate Prodecis, its genomics-based personalized analysis, into Palo Alto, California-based cancer-focused medical devices and software products specialist Varian Medical Systems' (NYSE: VAR) 360 Oncology care management software platform, the company said.
Prodecis will enable 360 Oncology to deliver genomics-based evidence to help clinicians make more informed decisions.
Prodecis is a clinical-grade multifactor decision support system integrating all currently available patient data to allow personalized treatment of cancer.
The predictive models based on toxicity, tumor control, quality of life and cost effectiveness, enhance the ability of 360 Oncology to provide the information needed by a clinician to recommend the optimal individualized treatment for each patient.
DNAmito, headquartered in Palo Alto, California, has a significant presence in Europe through its ptTheragnostic R and D office in the Netherlands. DNAmito solutions provide genomics-based personalized analysis for radio-sensitivity to optimize radiation treatment for cancer.
Varian Medical Systems is a manufacturer of medical devices and software for treating and managing cancer. The company employs approximately 6,600 people around the world.